The UT San Antonio Health Science Center has been ranked No. 495 globally for its biomedical research, highlighting its impact on health worldwide. The institution's researchers have made significant breakthroughs in medicine, strengthening its reputation as a powerhouse of medical research.
The merged institution offers over 320 highly competitive degrees and certificates, with academic programs ranked among the top 3% worldwide. UT San Antonio's Health Science Center is a global leader in biomedical discovery and innovation.
A keto diet may have different effects on males and females, with estrogen found to promote protection against adverse effects such as cellular senescence. The study found that male mice on a keto diet showed increased markers of oxidative stress and cellular senescence, but these effects were reversed by estrogen treatment.
The UT Health San Antonio School of Nursing has earned the Center of Excellence in Nursing Education designation from the National League of Nursing for promoting pedagogical expertise. The school is one of only 21 programs nationally recognized for its innovative approach and commitment to diversity, equity, and inclusion.
Researchers create breakthrough imaging system that shows sensory activity in real time, enabling them to distinguish between different sensations. The technique uses a genetically encoded voltage sensor to observe electrical signals from neurons and has major implications for treating chronic pain and sensory disorders.
The UT Health San Antonio research team, led by Blake Rasmussen, has been selected as a semifinalist in the XPRIZE Healthspan competition. They will use a low-frequency ultrasound spa to develop a non-invasive treatment that helps renew cells and tissues, potentially improving overall health and longevity.
The Be Well Texas initiative, led by the University of Texas Health Science Center at San Antonio, will expand access to opioid use disorder treatment services and recovery support across rural and urban communities. This major statewide expansion aims to reduce overdose deaths and build a lasting recovery infrastructure.
A new urine-based tumor DNA test can help personalize bladder cancer treatment by predicting which patients are at higher risk for recurrence after immunotherapy. The test, UroAmp, analyzes urine samples to identify bladder cancer-related mutations and generate a genomic profile for each patient.
The University of Texas Health Science Center at San Antonio is targeting hard-to-treat cancers and boosting HPV vaccination rates with a $3.4 million funding from CPRIT. The institution will expand its core facilities laboratories to increase researchers' ability to identify therapeutic targets and develop new cancer technologies.
Researchers at UT Health San Antonio have made a major discovery in understanding cancer drug resistance, specifically in BRCA1-deficient cancers treated with PARP inhibitors. The study reveals that problems in the CST complex can cause resistance to these drugs, opening doors to new therapies and personalized treatments.
The UT Health San Antonio Multispecialty and Research Hospital is the first in Texas to approve use of suzetrigine, a new non-opioid medication for post-surgical pain. This medication targets the peripheral nervous system, avoiding opioid-related side effects.
Researchers at UT Health San Antonio discovered associations between blood lipid levels and Alzheimer's disease risk. Higher small dense cholesterol particles increased risk, while ApoB48 levels were associated with lower risk.
Researchers found that post-menopausal women with high midlife cortisol levels have increased amyloid deposition and are at greater risk for Alzheimer's disease. The study also highlights the importance of identifying early risk factors in women, particularly those who experience menopause.
Long sleep duration is associated with poorer global cognition and specific cognitive abilities like memory, visuospatial skills and executive functions. This association is strongest in people with depressive symptoms, regardless of antidepressant usage.
Researchers at the University of Texas Health Science Center at San Antonio have discovered a crucial pathway to preserve thymic function as we age. The study found that increasing fibroblast growth factor FGF21 can help maintain thymus size and function, allowing for a broader range of T-cells to develop.
Researchers discovered that individuals with robust immune resilience at midlife can gain a 15.5-year survival advantage due to their ability to counter disease drivers and maintain healthy aging. The study highlights the importance of salutogenesis, or promoting health and well-being from birth to approximately age 70.
A UT Health San Antonio-led discovery could redefine drug discovery by turning IV medications into orally administered treatments for brain cancer, Alzheimer’s disease, and other complex conditions. The new strategy uses a protein receptor called CD36 to efficiently deliver large molecules into cells.
Researchers at UT Health San Antonio have identified a novel drug target for acute myeloid leukemia, which showed significant delays in disease progression and improved survival rates. The protein paraspeckle component 1 (PSPC1) plays a crucial role in the disease, and targeting it may offer new treatment options for AML patients.
Researchers at UT Health San Antonio are among the first to use adaptive deep brain stimulation technology that adjusts treatment based on a patient's symptoms. This innovative approach offers improved therapy and symptom optimization for patients with Parkinson's disease, dystonia, epilepsy, and essential tremor conditions.
Researchers at UT Health San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation by targeting senescent cells with experimental 'senolytic' drugs. This approach shows promise in preventing tumor growth and improving patient survival.
Researchers have discovered a novel imaging tool that captures functional activity in mouse models of TMJ injury and inflammation, revealing the simultaneous activity of over 3,000 trigeminal ganglion neurons. This finding suggests that CGRP antagonists could offer a promising solution for TMJ pain relief.
A new drug formulation called Rhenium Obisbemeda has been shown to significantly extend the median survival and progression-free time of glioblastoma patients, with a median overall survival time of 17 months. The treatment, which uses convection-enhanced delivery, shows promise as a potential cure for this deadly brain tumor.
A new drug candidate has been developed to target and eliminate senescent cells in the liver, reducing fat buildup and preventing liver damage. The study demonstrates a safer and more effective approach to treating metabolic dysfunction-associated steatotic liver disease (MASLD) and potentially inhibiting liver cancer development.
A new clinical trial will use MDMA in combination with Prolonged Exposure therapy to enhance treatment outcomes for individuals with PTSD. Researchers believe MDMA shows potential in improving PTSD symptoms by increasing neuroplasticity and processing traumatic memories.
A 30-year study analyzing Catholic nuns' aging patterns has clarified key factors influencing dementia risk and protection. The research found that early-life linguistic ability and grammatical complexity correlated with a lower risk of impairment in later life.
UT Health San Antonio has earned the prestigious Research 1 designation from the American Council on Education and the Carnegie Foundation for its exceptional research expenditures and number of doctoral degrees awarded. The institution has made significant strides in biomedical discovery, medical education, and economic growth.
A UT Health San Antonio researcher and her biotechnology company partner with the school to develop a breakthrough oral cancer drug, CIDD99. The partnership aims to create effective, less toxic cancer therapies for aggressive cancer types.
A recent study published in JAMA Network Open found that females aged 40-55 years have the highest risk of developing long COVID, with a 31% higher associated risk compared to males. The research, part of the NIH RECOVER initiative, suggests that patients and healthcare teams should consider sex differences when treating long COVID.
Researchers at UT Health San Antonio and The University of Texas at San Antonio have won the 2025 Hill Prizes for their groundbreaking work on non-opioid painkillers and emergency airway management. The $500,000 prize funding will support the development of novel analgesics and a new design for endotracheal tubes.
A four-year study on eating disorders in older Hispanic women, funded by the NIH, aims to reduce multimorbidity and pioneer scalable interventions. Researchers will assess the impact of binge eating disorders on mental and physical health.
The book highlights innovative strategies for addressing Latino cancer disparities, including risk assessment, prevention, screening, detection, diagnosis, treatment, survivorship, and policy. It also shares model programs and resources to shape future efforts to address cancer among Latinos and all people.
A new study by UT Health San Antonio found that a smartphone app can help patients with opioid use disorder reduce their days of opioid use and stay in treatment longer. The app combined contingency management behavioral therapy and recovery support from peers, reducing opioid use by 35% compared to medication only.
Researchers found that antibodies targeting a specific site on the malaria parasite's virulence protein bind to the human host's endothelial protein C receptor, neutralizing the parasite. The discovery provides new insights into prevention and treatment of severe malaria.
The 47th San Antonio Breast Cancer Symposium is the world's largest breast cancer research conference, attracting over 11,000 attendees from 102 countries. The event showcases groundbreaking discoveries in drug development and advances care for underserved populations.
A UT Health San Antonio study found that brain volume changes correlate with social behavior differences in psychiatric conditions such as autism spectrum disorder and schizophrenia. Tbx1 deficiency was associated with decreased brain volume in the amygdala and surrounding cortical regions, affecting desire for social interaction.
A new neuroimaging marker, peak-width of skeletonized mean diffusivity (PSMD), has been validated as a susceptibility/risk biomarker for small vessel disease contributing to cognitive impairment and dementia. The study found that PSMD explained cognitive status above and beyond white matter hyperintensities.
UT Health San Antonio is the largest academic research institution in South Texas, producing over 2,300 scientific publications annually. The university has more than 550 clinical trials underway, advancing knowledge in critical fields such as Alzheimer's disease, cancer, and mental health.
The new hospital will provide patient-centered care with personalized, compassionate treatment and groundbreaking research. Patients will have access to top specialists and pioneering therapies in cancer treatment.
A new study by UT Health San Antonio reveals that BRCA1 plays a crucial role in promoting error-free DNA repair through the activation of end resection enzymes. This understanding sheds light on the tumor suppressor function of BRCA1 and has important implications for breast and other cancers.
Researchers discovered a gene-mutation pathway that can lead to targeted therapies for blood cancers. The TET2 gene's enzymatic activity regulates chromatin state and leukaemogenesis, providing new therapeutic targets.
A new study by UT Health San Antonio found that higher levels of leptin are associated with better signal-transmitting brain white matter in middle-aged adults. The researchers also discovered a link between leptin bioavailability and reduced risk of cognitive impairment, providing potential insights into obesity's role in dementia.
Researchers identified known genetic variants for Alzheimer’s disease as risk factors for all-cause dementia and vascular dementia. The study also found a substantial genetic overlap with vascular dementia and cerebral small-vessel disease.
A study by UT Health San Antonio urologist Ronald Rodriguez found that combining valproic acid, an anti-seizure medication, with DHA, a type of omega-3 fatty acid, may reduce the risk of contracting COVID-19 and lessen its severity. The combination has been shown to activate ancient antiviral pathways against coronaviruses.
A study published in Science Signaling explains the mechanism behind persistent pain related to obstructive sleep apnea. The researchers created a chronic intermittent hypoxia environment in mice and observed an increase in cytokines, which cause sensitivity in nociceptors producing prolonged pain sensitivity.
A trial at UT Health San Antonio found that Sacituzumab Govitecan was well-tolerated and showed signs of effectiveness for patients with breast cancer who had progressed to brain tumors. The drug has been shown to deliver a topoisomerase inhibitor into tumors, providing promising clinical signals of efficacy.
Researchers have developed a humanized mouse model with a fully functional human immune system, enabling the study of immunotherapy development, disease modeling, and vaccine development. The new model, called TruHuX, mounts specific antibody responses and can develop full-fledged systemic lupus autoimmunity.
Researchers found a causal link between cerebral small-vessel disease and increased risk of Alzheimer's and dementia. The study highlights the importance of white matter hyperintensity burden as a surrogate marker for clinical trials to prevent dementia.
A new study led by UT Health San Antonio found that long-term ketogenic diets can induce senescence, or aged cells, in normal tissues, affecting heart and kidney function. However, an intermittent ketogenic diet regimen eliminated these pro-inflammatory effects.
Researchers discovered ERMA, a cellular transport 'pump', plays a crucial role in guiding magnesium to heart cells. Targeting ERMA could lead to new treatments for heart conditions by maintaining stable calcium balances.
Researchers found that parents with high chemical intolerance scores were 5.7 times more likely to report a child with autism, highlighting the potential preventive role of avoiding toxic exposures. The study also suggests that reducing exposure prior to and during pregnancy could help prevention.